InfoBank

InfoBank operates a strange but useful hybrid: it runs a profitable enterprise messaging business in South Korea while writing pre-seed and seed checks into B2B SaaS and AI-driven startups out of its Seongnam headquarters. That dual identity is the point. Founders pitching InfoBank are talking to a corporate that has run real revenue across Korean enterprise channels for decades, and that perspective shapes which AI products it backs and how it expects them to reach customers. The fund treats messaging, communications, and workflow infrastructure as adjacent ground worth seeding aggressively rather than abstract markets to study from a distance.

Within healthcare, the focus is software rather than therapeutics. AI/ML in healthcare and health IT software are the two declared sub-verticals, which lines up with InfoBank’s broader B2B SaaS bias. Expect interest in clinical workflow tools, automation layered on existing hospital systems, and AI features that ride into Korean and Asian enterprises through messaging and communication channels InfoBank already understands. Founders building consumer wellness apps or hardware-heavy diagnostics are not the target. Founders building software that has to be sold into a CIO, a hospital IT department, or a regulated enterprise buyer are.

Check sizes sit under $250k, and the fund concentrates on pre-seed and seed rounds. That places InfoBank at the entry-point end of the cap table, often before product-market fit, and usually alongside other Korean and regional seed investors rather than as the sole institutional lead. The accelerator-style posture matters here: InfoBank tends to be active rather than passive, expecting to plug founders into its own enterprise channels and customer relationships rather than simply wiring money and waiting. Geographically the center of gravity is South Korea, with selective interest in companies that can plug into the Korean enterprise stack or expand from Korea outward into the rest of Asia.

The team is built around InfoBank’s operating heritage rather than a roster of career investors. That means founders should expect questions from people who have actually shipped enterprise messaging products at scale, signed contracts with Korean conglomerates, and navigated the local procurement bureaucracy that often decides whether a healthcare software pilot survives. The diligence flavor leans practical and commercial: how the product fits into a real buyer’s workflow, what the integration path looks like, and how a Korean go-to-market motion would unfold in the first eighteen months.

For founders, the practical read is that InfoBank is a sharp choice if you want a Korean corporate seed investor that can open enterprise doors and is willing to be aggressive at the earliest stages. It is less useful if you need a large lead check, deep US clinical relationships, or biotech regulatory expertise. The accelerator framing should be taken seriously rather than as marketing language: founders backed by InfoBank are typically expected to lean on the parent company’s distribution and customer base, and to treat the relationship as more than a passive financial investment. Founders who want a quiet checkbook will fit better elsewhere; founders who want a Korean operating partner at the seed stage will find the model rare and worth the conversation.